ELUVIA™
Drug-Eluting Vascular Stent System
C U R R E N T L Y E N R O L L I N G P A T I E N T S
Trial Design
- Prospective, multicenter 2:1 randomized control trial (Eluvia : Zilver™ PTX)
- 485 patients at up to 75 investigational sites worldwide
- 5 year follow-up
Objective
Evaluate the safety and effectiveness of the Boston Scientific Eluvia Drug-Eluting Vascular Stent System (Eluvia Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length.